Evidence map›Paper›PMID 37933090›Full record

ArticleJournal of medical virology2023

Activation of Toll-like receptor 3 inhibits HIV infection of human iPSC-derived microglia.

Peng Wang, Jin-Biao Liu, Xu Wang, Feng-Zheng Meng, Qian-Hao Xiao, Lu Liu, Jian Zhu, Wen-Hui Hu, Wen-Zhe Ho

Open access · bronzeAbstract read
In one paragraph

Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Methamphetamine enhances HIV infection of human iPSC-derived microglia.NeuroImmune pharmacology and therapeutics · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Peng WangDepartment of Pathology and Laboratory Medicine, Temple University LewisKatz School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-8695-6721
Jin-Biao LiuDepartment of Pathology and Laboratory Medicine, Temple University LewisKatz School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-8973-4331
Xu WangDepartment of Pathology and Laboratory Medicine, Temple University LewisKatz School of Medicine, Philadelphia, Pennsylvania, USA.
Feng-Zheng MengDepartment of Pathology and Laboratory Medicine, Temple University LewisKatz School of Medicine, Philadelphia, Pennsylvania, USA.
Qian-Hao XiaoDepartment of Pathology and Laboratory Medicine, Temple University LewisKatz School of Medicine, Philadelphia, Pennsylvania, USA.
Lu LiuCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
Jian ZhuDepartment of Pathology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID 0000-0001-9856-8320
Wen-Hui HuDepartment of Pathology and Laboratory Medicine, Temple University LewisKatz School of Medicine, Philadelphia, Pennsylvania, USA.
Wen-Zhe HoDepartment of Pathology and Laboratory Medicine, Temple University LewisKatz School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-5235-0606
Temple University · USThe Ohio State University Wexner Medical Center · US

Funding

HIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral OrganoidsR01DA051893 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI HO, WENZHE, HU, WENHUI · 2020 to 2024
$3.1M
Long-term microglia-targeted endogenous retrovirus-like particle (ERVLP) delivery of Cas12f editor to cure HIVR01DA056876 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Wenhui Hu · 2022 to 2026
$3.0M
Investigate Host Gene Isoforms Contributing to HIV Persistence in Cocaine UsersR01DA059538 · NIDA · OHIO STATE UNIVERSITY · PI Wei Jiang, Jian Zhu · 2023 to 2026
$2.9M
Target Host Epigenetic Regulation of HIV Proviruses to Reinforce Viral Deep Latency in MicrogliaR01MH134402 · NIMH · OHIO STATE UNIVERSITY · PI HO, WENZHE, ZHU, JIAN · 2023 to 2025
$2.2M
Role of miRNAs in Methamphetamine/HIV-mediated Immune ActivationR01DA045568 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI HO, WENZHE · 2018 to 2022
$2.0M
Effect of Methamphetamine and/or HIV on Human iPSCs-derived microglia and NeuronR21DA051396 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI HO, WENZHE · 2020 to 2021
$436k
Role of RNA Methylation in Regulating HIV Proviral ExpressionR56AI157872 · NIAID · OHIO STATE UNIVERSITY · PI ZHU, JIAN · 2021 to 2021
$374k
NIAID NIH HHS R56 AI157872NIDA NIH HHS R01 DA045568NIDA NIH HHS R01 DA051893NIDA NIH HHS R01 DA056876NIDA NIH HHS R21 DA051396NIMH NIH HHS R01 MH134402
6 · The paper itself

Abstract

As a key immune cell in the brain, microglia are essential for protecting the central nervous system (CNS) from viral infections, including HIV. Microglia possess functional Toll-like receptor 3 (TLR3), a key viral sensor for activating interferon (IFN) signaling pathway-mediated antiviral immunity. We, therefore, studied the effect of poly (I:C), a synthetic ligand of TLR3, on the activation of the intracellular innate immunity against HIV in human iPSC-derived microglia (iMg). We found that poly (I:C) treatment of iMg effectively inhibits HIV infection/replication at both mRNA and protein levels. Investigations of the mechanisms revealed that TLR3 activation of iMg by poly (I:C) induced the expression of both type I and type III IFNs. Compared with untreated cells, the poly (I:C)-treated iMg expressed significantly higher levels of IFN-stimulated genes (ISGs) with known anti-HIV activities (ISG15, MxB, Viperin, MxA, and OAS-1). In addition, TLR3 activation elicited the expression of the HIV entry coreceptor CCR5 ligands (CC chemokines) in iMg. Furthermore, the transcriptional profile analysis showed that poly (I:C)-treated cells had the upregulated IFN signaling genes (ISG15, ISG20, IFITM1, IFITM2, IFITM3, IFITM10, APOBEC3A, OAS-2, MxA, and MxB) and the increased CC chemokine signaling genes (CCL1, CCL2, CCL3, CCL4, and CCL15). These observations indicate that TLR3 is a potential therapy target for activating the intracellular innate immunity against HIV infection/replication in human microglial cells. Therefore, further studies with animal models and clinical specimens are necessary to determine the role of TLR3 activation-driven antiviral response in the control and elimination of HIV in infected host cells.

Indexed as

HIV InfectionsInduced Pluripotent Stem CellsMicrogliaToll-Like Receptor 3Cells, CulturedHumansImmunity, InnatePoly I-CPoly I-CTLR3 protein, humanToll-Like Receptor 3HIVinterferoniPSC-derived microgliapoly (I:C)TLR3

Identifiers

PMID37933090
PMCPMC10655899
OpenAlexW4388461194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.